Volastra Therapeutics has announced data identifying p16 loss as a candidate predictive biomarker for KIF18A inhibition, establishing a pan-cancer development strategy for its therapies. The findings were disclosed around the American Association for Cancer Research Annual Meeting 2026. The clinical-stage oncology company released a study analysing 79 heavily pretreated high-grade serous ovarian cancer patients treated with KIF18A inhibitors sovilnesib and VLS-1488. Biomarker-positive tumours showed significant enrichment for objective responses, durable disease control and longer progression-free survival. The research identifies Rb pathway inactivation as the mechanistic basis of response to KIF18A inhibition, potentially applicable to approximately 15% of human cancers. Volastra's proprietary p16 IHC biomarker strategy aims to translate this biology into clinical patient selection across multiple tumour types.

NEW YORK - may 27, 2025 - Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the appointment of David P. Southwell as Chief Executive Officer.